Abstract
The para-methoxybenzyl-substituted titanocene oxalate (Oxali-Titanocene Y) was tested in vitro in an antiangiogenesis assay against human umbilical vein endothelial cells, HUVEC, delivering an IC50 value of 14 μM and in a cytotoxicity assay against the human renal cancer cells, CAKI-1, which demonstrated an IC50 value greater than 100 μM. Then Oxali-Titanocene Y was given at 30 mg/kg/d, which is the maximum tolerable dose, on five consecutive days per week for three weeks to one cohort of eight CAKI-1 tumor-bearing female NMRI:nu/nu mice, while a second cohort was treated with solvent only. The titanocene-treated mouse cohort showed a statistically significant tumor growth reduction with respect to the solvent-treated control group with an optimal T/C value of 38% at the end of the experiment. Immunohistological analysis revealed that the expression of the proliferation marker Ki-67 was reduced by 30%. Furthermore, an anti-angiogenic activity was identified by CD31 staining; the number of micro vessels in a defined tumor area was significantly decreased due to Oxali-Titanocene Y treatment.
Keywords: Anti-cancer drug, Titanocene, Renal-cell cancer, CAKI-1, Cytotoxicity, Xenograft, HUVEC, Anti-angiogenesis
Letters in Drug Design & Discovery
Title: Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
Volume: 5 Issue: 8
Author(s): Iduna Fichtner, Diana Behrens, James Claffey, Brendan Gleeson, Megan Hogan, Denise Wallis, Holger Weber and Matthias Tacke
Affiliation:
Keywords: Anti-cancer drug, Titanocene, Renal-cell cancer, CAKI-1, Cytotoxicity, Xenograft, HUVEC, Anti-angiogenesis
Abstract: The para-methoxybenzyl-substituted titanocene oxalate (Oxali-Titanocene Y) was tested in vitro in an antiangiogenesis assay against human umbilical vein endothelial cells, HUVEC, delivering an IC50 value of 14 μM and in a cytotoxicity assay against the human renal cancer cells, CAKI-1, which demonstrated an IC50 value greater than 100 μM. Then Oxali-Titanocene Y was given at 30 mg/kg/d, which is the maximum tolerable dose, on five consecutive days per week for three weeks to one cohort of eight CAKI-1 tumor-bearing female NMRI:nu/nu mice, while a second cohort was treated with solvent only. The titanocene-treated mouse cohort showed a statistically significant tumor growth reduction with respect to the solvent-treated control group with an optimal T/C value of 38% at the end of the experiment. Immunohistological analysis revealed that the expression of the proliferation marker Ki-67 was reduced by 30%. Furthermore, an anti-angiogenic activity was identified by CD31 staining; the number of micro vessels in a defined tumor area was significantly decreased due to Oxali-Titanocene Y treatment.
Export Options
About this article
Cite this article as:
Fichtner Iduna, Behrens Diana, Claffey James, Gleeson Brendan, Hogan Megan, Wallis Denise, Weber Holger and Tacke Matthias, Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice, Letters in Drug Design & Discovery 2008; 5 (8) . https://dx.doi.org/10.2174/157018008786898545
DOI https://dx.doi.org/10.2174/157018008786898545 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Preface: Additional Potential Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Antagonists
Current Pharmaceutical Design Immunotherapy of Kidney Cancer
Current Clinical Pharmacology Control of Mycobacterium tuberculosis Infection by Glutathione
Recent Patents on Anti-Infective Drug Discovery XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Effect of Cytostatic Drugs on the mRNA Expression Levels of Ribonuclease κ in Breast and Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Implication of CYP24A1 Splicing in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design Absorption, Disposition and Pharmacokinetics of Nanoemulsions
Current Drug Metabolism p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Letters in Drug Design & Discovery Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry